2.74
+0.32(+13.22%)
Currency In USD
| Previous Close | 2.42 |
| Open | 2.53 |
| Day High | 2.82 |
| Day Low | 2.53 |
| 52-Week High | 11.46 |
| 52-Week Low | 1.07 |
| Volume | 7.24M |
| Average Volume | 5.51M |
| Market Cap | 254.07M |
| PE | -2.91 |
| EPS | -0.94 |
| Moving Average 50 Days | 8.2 |
| Moving Average 200 Days | 5.97 |
| Change | 0.32 |
If you invested $1000 in Rezolute, Inc. (RZLT) 10 years ago, it would be worth $43.84 as of December 25, 2025 at a share price of $2.74. Whereas If you bought $1000 worth of Rezolute, Inc. (RZLT) shares 5 years ago, it would be worth $186.39 as of December 25, 2025 at a share price of $2.74.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
GlobeNewswire Inc.
Dec 11, 2025 12:00 PM GMT
Study did not meet the primary or key secondary endpoint 45% reduction in hypoglycemia events observed at top ersodetug dose (10 mg/kg) compared to 40% improvement in placebo arm Management to host conference call today at 8:30am ET REDWOOD CITY, Ca
Rezolute to Host Virtual Investor Event on Ersodetug Development Program
GlobeNewswire Inc.
Nov 05, 2025 12:30 PM GMT
Webcast scheduled for Monday, November 10 at 12:00 pm ESTREDWOOD CITY, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused
Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Oct 09, 2025 8:05 PM GMT
REDWOOD CITY, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ: RZLT), (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that it has granted